EMINENT was founded in 1997 as a Maryland Corporation, to assist the emerging pharmaceutical and biotechnology companies as well as institutional and CROs in meeting clinical drug regulatory issues while planning Phase I, II, and III clinical studies as well as providing a practical solution in addressing comprehensive clinical management services (product development and stability testing, clinical manufacturing, patient specific presentation, randomization, distribution, drug product monitoring at the clinical site level, patient compliance monitoring, return drug accountability, biological specimen storage) and infotech services in a timely and cost-effective manner. EMINENT has been audited by many regulatory agencies including FDA/EMEA/PMDA/ANVISA/DEA, etc.